ViewsML has successfully closed an oversubscribed $4.9M seed round, marking a major milestone in their mission to transition tissue analysis from a manual laboratory task into a high-performance software solution.
As a repeat investor, we are proud to continue our partnership with ViewsML. Their innovative platform is establishing the world’s first virtual biomarker library, using sophisticated AI to generate spatial, per-cell insights directly from standard pathology slides. By virtualizing the staining process, they have eliminated one of the most persistent bottlenecks in drug development: slashing the time required for biomarker analysis from weeks down to just a few minutes.
This new injection of capital will allow the team to scale their commercial operations and deepen strategic collaborations.
Read the full announcement and learn more here.